The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced a new license agreement aimed at advancing dual-purpose candidate vaccines to protect against rabies and Ebola viruses. The vaccines were created by scientists at NIAID and Thomas Jefferson University (TJU) in Philadelphia and are being further developed through a partnership with the German pharmaceutical company IDT Biologika. The candidate vaccines now have been licensed to Exxell BIO of Saint Paul, Minnesota, which aims to advance the products through clinical testing and commercialization.
NIAID Director Anthony S. Fauci, M.D., and Joseph Blaney, Ph.D., M.B.A., a staff scientist in the Division of Intramural Research, are available to discuss development of the vaccines.
To schedule interviews, please contact Hillary Hoffman, (301) 402-1663, firstname.lastname@example.org.